Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Lam Research
LRCX
|
$792M |
| 2 |
Johnson & Johnson
JNJ
|
$659M |
| 3 |
Datadog
DDOG
|
$571M |
| 4 |
Amazon
AMZN
|
$474M |
| 5 |
Broadcom
AVGO
|
$458M |
Top Sells
| 1 |
Workday
WDAY
|
$1.23B |
| 2 |
AbbVie
ABBV
|
$1.03B |
| 3 |
Advanced Micro Devices
AMD
|
$686M |
| 4 |
Honeywell
HON
|
$673M |
| 5 |
Amgen
AMGN
|
$620M |
Sector Composition
| 1 | Technology | 34.72% |
| 2 | Healthcare | 17.58% |
| 3 | Consumer Discretionary | 10.69% |
| 4 | Financials | 10.22% |
| 5 | Communication Services | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LINE
201
Lineage, Inc. Common Stock
LINE
$9.26B
| $189M | 0.1% |
3,233,219
+1,550,478
| +92% | +$90.8M |
|
202
Humana
HUM
$37.5B
| $184M | 0.09% |
724,404
-179,044
| -20% | -$45.4M |
|
203
Freeport-McMoran
FCX
$66.1B
| $182M | 0.09% |
4,776,449
-395,770
| -8% | -$15.1M |
|
204
AXIS Capital
AXS
$7.76B
| $181M | 0.09% |
2,042,925
+20,976
| +1% | +$1.86M |
|
205
Walker & Dunlop
WD
$2.84B
| $179M | 0.09% |
1,845,100
+8,571
| +0.5% | +$833K |
|
206
Alibaba
BABA
$312B
| $179M | 0.09% |
2,112,187
+1,030,999
| +95% | +$87.4M |
|
207
Dyne Therapeutics
DYN
$1.88B
| $174M | 0.09% |
7,379,309
+566,146
| +8% | +$13.3M |
|
208
Zai Lab
ZLAB
$3.34B
| $172M | 0.09% |
6,567,892
-2,192,182
| -25% | -$57.4M |
|
209
S&P Global
SPGI
$165B
| $172M | 0.09% |
344,856
+55,376
| +19% | +$27.6M |
|
210
Crown Holdings
CCK
$10.7B
| $169M | 0.09% |
2,044,383
-778,711
| -28% | -$64.4M |
|
211
Akero Therapeutics
AKRO
$3.52B
| $168M | 0.09% |
6,034,239
-1,043,239
| -15% | -$29M |
|
212
Trip.com Group
TCOM
$47.7B
| $166M | 0.08% |
2,412,761
+471,768
| +24% | +$32.4M |
|
213
United Therapeutics
UTHR
$17.2B
| $165M | 0.08% |
468,996
+8,577
| +2% | +$3.03M |
|
214
Glaukos
GKOS
$5.17B
| $164M | 0.08% |
1,092,417
-233,367
| -18% | -$35M |
|
215
Sensient Technologies
SXT
$4.79B
| $161M | 0.08% |
2,257,033
+25,230
| +1% | +$1.8M |
|
216
IBM
IBM
$230B
| $160M | 0.08% |
729,479
-141,585
| -16% | -$31.1M |
|
217
Cisco
CSCO
$269B
| $159M | 0.08% |
2,687,382
-16,567
| -0.6% | -$980K |
|
|
SUM
218
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $157M | 0.08% |
3,096,383
+324,902
| +12% | +$16.4M |
|
219
Philip Morris
PM
$251B
| $156M | 0.08% |
1,297,023
+831,580
| +179% | +$100M |
|
220
Ryan Specialty Holdings
RYAN
$7.04B
| $156M | 0.08% |
2,431,193
-717,723
| -23% | -$46M |
|
221
Stride
LRN
$7.08B
| $155M | 0.08% |
1,493,709
+323,275
| +28% | +$33.6M |
|
222
Shift4
FOUR
$6.01B
| $151M | 0.08% |
1,456,002
+2,202
| +0.2% | +$229K |
|
223
IDEAYA Biosciences
IDYA
$2.26B
| $151M | 0.08% |
5,857,639
+695,263
| +13% | +$17.9M |
|
224
Ares Management
ARES
$39.5B
| $150M | 0.08% |
845,307
-23,707
| -3% | -$4.2M |
|
225
Magnolia Oil & Gas
MGY
$4.56B
| $150M | 0.08% |
6,396,875
+667,973
| +12% | +$15.6M |
|